Leukaemia Foundation media releases. | Leukaemia Foundation - Part 4

Latest news

Australia’s National Blood Cancer Taskforce meets for first time

Monday September 30 2019

The Leukaemia Foundation established the Blood Cancer Taskforce with the support of the Federal Government to develop Australia’s first National Strategic Action Plan for Blood Cancer.

Co-chaired by Bill Petch (CEO, Leukaemia Foundation) and Professor John Seymour (Director of Cancer Medicine, Clinical Research and Haematology, Peter MacCallum

Read More

Chronic myeloid leukaemia to affect five times as many Australians and take three times as many lives by 2035

Friday September 20 2019

A recent report released by the Leukaemia Foundation has found more than five times as many Australians will be diagnosed with chronic myeloid leukaemia come 2035, and the number of Australians losing their life to the rare blood cancer will more than triple.

The report shows

Read More

Swab a cheek to save a life, this World Marrow Donor Day

Friday September 20 2019

Every year, more than 600 Australians living with blood cancer will need an allogeneic stem cell transplant to survive.

To access that life-saving treatment, some patients will find a stem cell donor within their own family. However, 70 per cent rely on a complete stranger to donate

Read More

Bridgestone network reaffirms Leukaemia Foundation support through new funding initiative

Wednesday 18 September 2019

Australia’s most trusted tyre brand, Bridgestone, and its nation-wide network of Bridgestone retail stores, has announced a three-year extension with long-term charity partner, the Leukaemia Foundation. The declaration coincides with the launch of a new way for

Read More

World Awareness Day for Australia’s most common blood cancer

Sunday 15 September 2019

A recent report released by the Leukaemia Foundation has revealed the true size and impact of the blood cancer lymphoma in Australia is far greater than was previously known. 

The report shows currently around 6500 Australians will be diagnosed every year with a lymphoma making it Australia’s most common

Read More

Leukaemia Foundation shines spotlight on National MPN Awareness Day today

The Leukaemia Foundation is today honoring Australians living with the rare blood disorder Myeloproliferative Neoplasms (MPNs) as part of National MPN Awareness Day.

MPNs are just some of the many rare blood disorders which are seeing a rise in incidence, prevalence and mortality. More than 1205 Australians are diagnosed with

Read More

New national report reveals impact of blood cancer

Sunday 1 September 2019

A first-of-its-kind nationwide report commissioned by the Leukaemia Foundation reveals the true size, scale and impact of blood cancer and the lived experiences of people living with blood cancer in Australia today.

The Leukaemia Foundation has today marked the start of Blood Cancer

Read More

Local legacy to help fund blood cancer researchers of tomorrow


Friday 23 August 2019

A generous legacy by the family of a Cleveland local will help the Leukaemia Foundation support the next generation of Australian blood cancer researchers.

Cor Frederik (10.9.1927 – 25.9.2017) was businessman, scholar, author, investor, art collector and company director with a flourishing accounting practice in Cleveland, a

Read More

Leukaemia Foundation to support award for world leading haematologists

Wednesday 21 August 2019

Two world leaders in haematology will receive awards supported by the Leukaemia Foundation at this year’s International Society of Experimental Haematology Honorific (ISEH) meeting this week.

Dr David Scadden and Dr David Traver will be presented at ISEH’s Annual Scientific Meeting to be held in Brisbane from

Read More

Million-dollar investment into incurable blood cancer announced as Light the Night launches this week

Tuesday 6 August 2019

The Leukaemia Foundation will unveil a million-dollar investment into Strategic Ecosystem Research Partnership (SERP) grants which will use new state-of-the-art immunotherapy techniques, new drug design and molecular technology to understand the mechanisms of relapse and continue to drive rapid advancements in treatments for the incurable blood cancer, myeloma.


Read More

Share this page